Acanthamoeba Keratitis Clinical Trial
Official title:
Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction
Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus cross-linking with rose Bengal (RB-PDT). Patients presenting to one of the Aravind Eye Hospitals in India or to the Federal University of São Paulo ophthalmology clinic in Brazil with either smear or culture positive fungal or acanthamoeba keratitis or smear and culture negative corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of two treatment groups: Group 4, Sham RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT Group 5, RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02506257 -
Safety and Tolerability of Preservative-free Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06332703 -
Acanthamoeba and Artificial Intelligence
|
||
Enrolling by invitation |
NCT03461978 -
Ultrahigh-resolution Optical Coherence Tomography Imaging of the Anterior Eye Segment Structures
|
N/A | |
Recruiting |
NCT02763605 -
Retrospective Study of Acanthamoebic Keratitis During the Past 10 Years
|
N/A | |
Active, not recruiting |
NCT03484507 -
Parasitic Ulcer Treatment Trial Pilot
|
Phase 2 | |
Completed |
NCT03274895 -
Polihexanide (PHMB) Eye Drops in Patients Affected by Acanthamoeba Keratitis
|
Phase 3 | |
Not yet recruiting |
NCT06213649 -
Parasitic Ulcer Treatment Trial
|
Phase 3 |